15 April 1993 | Volume 118 Issue 8 | Pages 587-592
Objective: To determine the incidence of acute mountain sickness in a general population of visitors to moderate elevations, the characteristics associated with it, and its effect on physical activity.
Design: A cross-sectional study.
Setting: Resort communities located at 6300 to 9700 feet elevation in the Rocky Mountains of Colorado.
Participants: Convenience sample of 3158 adult travelers, 16 to 87 years old (mean age [±SD], 43.8 ± 11.8 years).
Results: Twenty-five percent of the travelers to moderate elevations developed acute mountain sickness, which occurred in 65% of travelers within the first 12 hours of arrival. Fifty-six percent of those with symptoms reduced their physical activity. The odds favoring acute mountain sickness were 3.5 times as large for visitors whose permanent residence was below 3000 feet elevation as for those whose residence was above 3000 feet; 2.8 times as large for visitors with previous symptoms of acute mountain sickness; and twice as large in travelers younger than 60 years. Women, obese persons, those in poor or average physical condition, and those with underlying lung disease also had a higher occurrence of acute mountain sickness (P < 0.05).
Conclusions: Acute mountain sickness occurs in 25% of visitors to moderate altitudes and affects activity in most symptomatic visitors. Persons who are younger, less physically fit, live at sea level, have a history of acute mountain sickness, or have underlying lung problems more often develop these symptoms.
More needs to be learned about the incidence of acute mountain sickness at moderate altitudes in the general population and about the characteristics of those most likely to be at risk for symptom development. We therefore surveyed groups of persons visiting resorts in the Colorado mountains for conferences and seminars. Specifically, we sought to determine 1) the incidence of acute mountain sickness in visitors exposed to moderate elevations; 2) the effect of acute mountain sickness on physical activity; and 3) the visitor characteristics associated with the development of acute mountain sickness. This information would be useful for developing strategies to minimize symptoms in travelers to moderate altitudes.
The questionnaire was completed by 3158 (75%) of the persons registered for these conferences, and information satisfactory for analysis was obtained from 99% of those completed. Visitors ranged in age from 16 to 87 years (mean age [±SD], 657e43.8 ± 11.8 years) (Figure 1). Of the completed surveys, 2023 (64%) were conducted at resorts located at elevations over 9000 feet and 2603 (82%) were completed in the winter season (November through April). The study was approved by the Human Research Committee of the University of Colorado Health Sciences Center. ARTICLE
Acute Mountain Sickness in a General Tourist Population at Moderate Altitudes
Rapid ascent from low to high altitude is often followed by headache, fatigue, shortness of breath, sleeplessness, and anorexia, a symptom complex called acute mountain sickness. Although some of these symptoms may occur as a result of travel not associated with altitude, only 5% of adults traveling at sea level report similar symptoms [1]. A long-standing interest has existed in the study of acute mountain sickness because it affects a large number of mountain visitors [2-4] and can progress to the life-threatening conditions of high-altitude pulmonary edema or high-altitude cerebral edema [5]. Previous estimates of the incidence of acute mountain sickness have been obtained primarily from small groups of physically fit young men going to altitudes above 12 000 feet [2-4, 7-9]. Little information exists on the frequency and severity of the disorder in the general population at moderate altitudes, yet the population at risk is large. For example, more than 13 million persons visited the Colorado mountains in 1990 for business, conferences, or recreational activities including skiing, climbing, hiking, hunting, and fishing [10].
Methods
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
The study cohort consisted of 4212 adults attending 45 conferences at resorts located at elevations of 6300 to 9700 feet in the Rocky Mountains of Colorado from July 1989 to May 1991. Resorts were chosen on the basis of the willingness of conference organizers to participate. Conferences whose schedules required all participants to attend a meeting within 48 hours of arrival when the study questionnaire could be distributed were included. Study personnel attended these meetings, briefly introduced the study, and distributed the questionnaires. Questions by participants concerning acute mountain sickness or the effects of altitude on health were not answered until all questionnaires were collected. Completion of the survey usually took less than 10 minutes. The participants in each meeting were counted to calculate the response rate.
|
The questionnaire was designed to obtain demographic information concerning age, gender, height, weight, and permanent residence for each visitor; previous or current medications; and the duration of stops, if any, made en route. Questions asked regarding underlying health conditions included whether the participant had ever been treated for lung disease (asthma, bronchitis, or emphysema); heart conditions (angina or heart attacks); diabetes; high blood pressure; or pregnancy. Participants were asked "How do you rate your physical condition?" Responses were rated as great, good, average, or poor.
To determine whether participants had acute mountain sickness, they were asked if they had experienced any of the following symptoms while at the resort: loss of appetite, vomiting, shortness of breath, dizziness or lightheadedness, unusual fatigue, sleep disturbance (other than related to normal travel), and headache. If the response to headache was "yes," they were asked to describe it as mild or severe. Acute mountain sickness was defined as the presence of three or more of these symptoms in the setting of recent altitude exposure. This case definition was similar to that used by previous investigators [1, 2, 5, 6, 9, 12, 13] and is in accordance with the case definition recently developed and codified for international use by the International Hypoxia Symposium [14].
If participants had any of these symptoms of acute mountain sickness, they were asked to determine how the symptoms affected their activity. Response options included "no limitation," "reduced activity," and "required to stay in bed or room". A determination of symptom onset was assessed by asking participants "How long after arrival at the resort did symptoms begin?" Response options included "less than 12 hours," "12 to 24 hours," "25 to 48 hours," "49 to 72 hours," or "72 hours".
Alcohol use was measured as the number of beer, wine, or hard-liquor drinks consumed within the first 24 hours of arrival at the resort. Season was determined by the date of questionnaire administration, with winter defined as November through April in each of the study years. Body mass index was calculated as weight kg/in2 and was used to identify obese persons (women with a body mass index >27.3 and men with a body mass index >27.8) [11].
Persons with or without acute mountain sickness were compared using the Wilcoxon rank-sum test for ordinal variables and using the chi-square test for categoric variables. The Student t-test was used for normally distributed variables. The Fisher exact test was used for small sample sizes. Associations were considered significant at P < 0.05.
A forward, stepwise, multiple logistic regression analysis was used to examine the independent effects of participant characteristics on the occurrence of acute mountain sickness. All variables associated with the occurrence of acute mountain sickness at P < 0.25 were initially included in the regression analysis. Data acquired in year 2 (June 1990 to May 1991), comprising 1241 cases after the revision of the questions concerning underlying health conditions and habitual activity level before travel, were used for the regression analysis. Variables were dichotomized for ease in presentation. The adjusted odds ratios were computed with 95% confidence intervals (CIs). All calculations were done using the Statistical Analysis Systems statistical package (Cary, North Carolina) [15].
Results
|
|---|
|
|
|---|
|
Twenty-five percent (CI, 24.98% to 25.01%) of the visitors reported having three or more symptoms and thus met the case definition for acute mountain sickness, whereas 73% had at least one reported symptom. The most common symptom was headache, and the least common was vomiting (Figure 2). For most participants (65%), the onset of symptoms occurred within the first 12 hours after arrival at altitude; symptom onset occurred between 12 and 36 hours in 34% and after more than 36 hours in 1%. Most (58%) of those with symptoms took analgesics (for example, aspirin, acetaminophen, or ibuprofen). Although 44% of persons with acute mountain sickness had no reduction in activity, 51% had moderate activity reduction, and a small proportion (5%) stayed in bed.
|
Visitors whose permanent residence was at an elevation below 3000 feet were more likely to develop acute mountain sickness (see Table 1). The frequency with which it developed was inversely related to age and physical condition (Figure 3). Altitude visited and a previous history of acute mountain sickness were associated with an increased occurrence, whereas development was inversely related to alcohol consumption. Visitors who stopped over at lower elevations for more than 38 hours were less likely to develop acute mountain sickness than were those who did not. Obesity, female gender, and chronic lung disease were also associated with the development of acute mountain sickness.
|
The following nine variables were entered into the regression analysis as dichotomous variables: age (younger than 60 years), sex, altitude of permanent residence (below 3000 feet), obesity, lung disease, diabetes, overnight stops before arrival at the resort, previous symptoms during past altitude travel, and self-reported physical condition (poor or average). Although alcohol was statistically associated with acute mountain sickness, it was not included in the model because of the inability to exclude a temporal effect (that is, participants may have become sick and subsequently decided not to drink). The five independent predictors of acute mountain sickness, based on the logistic regression, were residence at an altitude less than 3000 feet; symptoms of acute mountain sickness during previous altitude travel; age younger than 60 years; physical condition self-assessed as poor or average; and the presence of lung disease. The goodness-of-fit chi-square value was 5.51 (P = 0.23, DF = 4), indicating a good fit of the logistic model. The odds ratios, each adjusted for the other variables in the model, are shown in Table 2.
|
Discussion
|
|---|
|
|
|---|
Because the symptoms of acute mountain sickness are relatively nonspecific, the extent to which the symptoms result from travel or minor illnesses rather than from altitude exposure needs to be addressed. The finding that the percentage of visitors with symptoms was greater at the highest elevations supports a direct relation between altitude and acute mountain sickness. In addition, the risk attributed to altitude in our study was 19% (acute mountain sickness in sea-level residents minus symptoms in visitors living at moderate elevations). This finding is similar to the attributable risk of 20% shown by Montgomery and colleagues [1] (incidence of 25% among travelers to high-altitude resorts compared with 5% among travelers to sea-level resorts).
Our finding of a 25% incidence of acute mountain sickness is similar to that noted by Montgomery and associates (25%) [9] and by Dean and coworkers (25%) [12]. The incidence of acute mountain sickness ranges from 12% to 60%, with higher figures reported with rapid ascent and more extreme altitudes [1-3, 6, 9, 12, 16].
According to our logistic regression model, the strongest predictors for the development of acute mountain sickness were permanent residence below 3000 feet and a history of acute mountain sickness during previous altitude ascent. A protective effect of residence at moderate elevations (5000 to 6000 feet) confirms previous observations that staging of altitude ascent reduces the incidence of acute mountain sickness [2, 17-20]. In addition, certain persons may have an inherent predisposition to recurrent acute mountain sickness, such as retention of fluid and relative hypoventilation [4, 21-24].
Other factors that had a major effect on increasing the risk for developing altitude illness were younger age, presence of lung disease, and poor physical condition. Increased susceptibility to acute mountain sickness among younger persons was also noted by Hackett and colleagues [2]. This finding is surprising because some physiologic components of gas exchange that maintain oxygenation, such as vital capacity and hypoxic ventilatory drive, decrease with age [25, 26]. Although not studied, elderly persons who visit high altitudes for recreational activities may be self-selected to include the more healthy persons who curtail their activities on arrival in ways that decrease the incidence of acute mountain sickness. The evidence that those visitors with underlying lung disease (for example, asthma, bronchitis, and chronic obstructive lung disease) had a higher incidence of acute mountain sickness supports the views of Hackett [6] and Houston [27]. Marginal gas exchange and abnormal pulmonary mechanics are expected to result in exaggerated hypoxia at high altitudes [3, 28-30]. Other underlying health conditions, such as heart disease, diabetes, and hypertension, did not appear to influence the risk for developing altitude illness in our study sample. It is not clear from our questionnaire, however, whether persons who were treated successfully for one or more of these conditions considered themselves to be healthy and therefore did not report the presence of the disease.
The influence of physical condition on the development of acute mountain sickness is unclear. Some studies suggest that the incidence is increased in those with greater baseline aerobic fitness [31], whereas others report that aerobic fitness increases a person's tolerance to altitude symptoms [6, 18]. Our measurement of physical fitness, although self-assessed and not a clinical measurement, supports an increased risk for acute mountain sickness among less fit persons. This information may be useful to clinicians in assessing the risk for acute mountain sickness in their practice and in developing educational material for the public.
Several articles and texts [6, 17, 27] recommend minimizing alcohol use to prevent or ameliorate altitude symptoms. Although our data seem to contradict the conventional wisdom that alcohol worsens the symptoms and increases the incidence of acute mountain sickness, our questionnaire could not exclude a temporal effect (that is, persons may develop symptoms and subsequently decide not to drink, or they may feel well initially and drink in excess). This area requires further investigation before changing standard recommendations.
Previous reports also have indicated that women are protected from acute mountain sickness [17, 32], perhaps because of the presence of higher levels of the ventilatory-stimulating hormone progesterone; other studies, however, do not show any sex difference [2, 8]. Our results do not support a gender-based advantage and provide evidence that an increased susceptibility to acute mountain sickness may exist among women.
Because more than one half (65%) of the visitors developed symptoms within the first 12 hours after arrival, health care providers, educators, and sojourners can use this information to initiate prophylactic and therapeutic measures early in their visits to higher altitudes to minimize these symptoms and to maximize their return to normal activity.
Although acute mountain sickness is usually a self-limited disease, approximately one half of the visitors with altitude illness reduced their activity and took analgesics to relieve their discomfort. These findings are important for an appreciation of the magnitude of the problem of altitude illness in the general population of visitors to the mountains of Colorado, other western states, and world regions for recreational activities in a mountainous setting. Our findings also provide insights into the economic impact of the disease and possible solutions for minimizing its occurrence or its severity. One strategy for minimizing the economic, personal, and medical impact of acute mountain sickness includes prophylactic and therapeutic interventions (for example, recommending a stopover at an intermediate altitude such as Denver [elevation, 5280 feet] for more than 38 hours, which, in our study, was associated with a reduction in the incidence from 27.5% to 22.5%). The drug acetazolamide has also been shown to be an effective prophylactic agent [2, 16, 33]. Participating in less strenuous activity immediately after arrival to the higher altitude also may be beneficial. Further understanding of the natural history, evolution, and risk factors associated with acute mountain sickness will help the clinician determine the appropriate prophylactic, educational, and therapeutic regimens to offer patients before travel to higher altitudes. In addition, these findings will help provide important recommendations for visitors and resort operators that can be immediately cost-effective, given the frequency of acute mountain sickness.
Acknowledgments: The authors thank Jack Reeves, Robert Schoene, Dick Nicholas, Jules Lickteig, Jim Kasik, Pat Pearce, and Terry Telander for their assistance and Steven R. Lowenstein for statistical analysis.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Montgomery AB, Mills J, Luce JM. Incidence of acute mountain sickness at intermediate altitude. JAMA. 1989; 261:732-6.
2. Hackett PH, Rennie D. The incidence, importance and prophylaxis of acute mountain sickness. Lancet. 1976; 2:1149-55.
3. Singh I, Khanna PK, Cardiology DM, Srivastava ML, Lal M, Roy SB, et al. Acute Mountain Sickness. N Engl J Med. 1969; 280:175-84.
4. Hackett PH, Rennie D, Hofmeister SE, Grover RF, Grover EB, Reeves JT. Fluid retention and relative hypoventilation in acute mountain sickness. Respiration. 1982; 43:321-9.
5. Moore LG. Altitude-aggravated illness: examples from pregnancy and prenatal life. Ann Emerg Med. 1987; 16:965-73.
6. Hackett PH, Roach RC, Sutton JR. High altitude medicine. In: Auerbach PS, Geehr EC; eds. Management of Wilderness and Environmental Emergencies. 2d ed. New York: C.V. Mosby; 1989:1-34.
7. Robinson SM, King AB, Aoki V. Acute mountain sickness: reproducibility of its severity and duration in an individual. Aerosp Med. 1971; 42:706-8.
8. Hackett PH, Rennie D. Rales, peripheral edema, retinal hemorrhage and acute mountain sickness. Am J Med. 1979; 67:214-8.
9. Houston CS. Incidence of acute mountain sickness. A study of winter visitors to six Colorado resorts. American Alpine Journal. 1985; 59:162-5.
10. Colorado Board of Tourism Annual Report. Denver: Colorado Board of Tourism; 1991.
11. Van Itallie TB. Health Implications of overweight and obesity in the United States. Ann Intern Med. 1985; 103:983-8.
12. Dean AG, Yip R, Hoffmann RE. High incidence of mild acute mountain sickness in conference attendees at 10000 foot altitude. Journal of Wilderness Medicine. 1990; 1:86-92.
13. Ferrazzini G, Maggiorini M, Kriemler S, Bartsch P, Oelz O. Successful treatment of acute mountain sickness with dexamethasone. Br Med J. 1987; 294:1380-2.
14. Lake Louise Consensus on Definition and Quantification of Altitude Illness. In: Sutton JR, Coates G, Houston CS; eds. Hypoxia: Mountain Medicine. Burlington, Vermont: Queen City Press; 1992: 327-30.
15. SAS Institute: Statistical analysis systems. Cary, North Carolina, SAS Institute.
16. Larson EB, Roach RC, Schoene RB, Hornbein TF. Acute mountain sickness and acetazolamide. JAMA. 1982; 248:328-32.
17. Johnson TS, Rock PB. Acute mountain sickness. N Engl J Med. 1988; 319:841-45.
18. Hackett PH, Rennie D. Acute mountain sickness. Seminars in Respiratory Medicine. 1983; 5:132-40.
19. Stamper DA, Sterner RT, Robinson SM. Evaluation of an acute mountain sickness questionnaire: effect of intermediate-altitude staging upon subjective symptomatology. Aviat Space Environ Med. 1980; 51:379-87.
20. Evans WO, Robinson SM, Horstman DH, Jackson RE, Weiskopf RB. Amelioration of the symptoms of acute mountain sickness by staging and acetazolamide. Aviat Space Environ Med. 1976; 47:512-6.
21. Heyes MP, Sutton JR. High altitude ills: a malady of water, electrolyte and hormone imbalance. Seminars in Respiratory Medicine. 1983; 5:207.
22. Harber MJ, Williams JD, Morton JJ. Antidiuretic hormone excretion at high altitude. Aviat Space Environ Med. 1981; 52:38-40.
23. King AB, Robinson SM. Ventilation response to hypoxia and acute mountain sickness. Aerosp Med. 1972; 43:419-21.
24. Moore LG, Harrison GL, McCullough RE, McCullough RG, Micco AJ, Tucker A, et al. Low acute hypoxic ventilatory response and hypoxic depression in acute altitude sickness. J Appl Physiol. 1986; 60:1407-12.
25. Dill DB, Hillyard SD, Miller J. Vital capacity, exercise performance, and blood gases at altitude as related to age. J Appl Physiol. 1980; 48:6-9.
26. Davies CT. The oxygen transporting system in relation to age. Clin Sci. 1972; 42:1-13.
27. Houston CS. Going Higher: The Story of Man at High Altitude. Boston: Little, Brown and Company; 1987.
28. Anholm JD, Houston CS, Hyers TM. The relationship between acute mountain sickness and pulmonary ventilation at 2,835 meters (9,300 ft). Chest. 1979; 75:33-6.
29. Lupi-Herrera E, Sandoval J, Seoane M, Bialostozky D. Behavior of the pulmonary circulation in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1982; 126:509-14.
30. Gong H Jr, Tashkin DP, Lee EY, Simmons MS. Hypoxia-altitude simulation test. Evaluation of patients with chronic airway obstruction. Am Rev Respir Dis. 1984; 130:980-6.[Medline]
31. Cymerman A, Jaeger JJ, Kobrik JL. Physical fitness and acute mountain sickness. Proceedings of the 1979 Hypoxia Symposium (Abstract). Calgary: Arctic Institute of North America; 1979:66.
32. Harris CW, Shields JL, Hannon JP. Acute altitude sickness in females. Aerosp Med. 1966; 37:1163-7.
33. Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med. 1987; 83:1024-30.
This article has been cited by other articles:
![]() |
R. B. Schoene Illnesses at High Altitude Chest, August 1, 2008; 134(2): 402 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. V. Serebrovskaya, E. B. Manukhina, M. L. Smith, H. F. Downey, and R. T. Mallet Intermittent Hypoxia: Cause of or Therapy for Systemic Hypertension? Experimental Biology and Medicine, June 1, 2008; 233(6): 627 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Bosch, D. Barthelmes, T. M. Merz, K. E. Bloch, A. J. Turk, U. Hefti, F. K. P. Sutter, M. Maggiorini, M. G. Wirth, O. D. Schoch, et al. High Incidence of Optic Disc Swelling at Very High Altitudes Arch Ophthalmol, May 1, 2008; 126(5): 644 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Jafarian, R Abolfazli, F Gorouhi, S Rezaie, and J Lotfi Gabapentin for prevention of hypobaric hypoxia-induced headache: Randomized double-blind clinical trial J. Neurol. Neurosurg. Psychiatry, March 1, 2008; 79(3): 321 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Muhm, P. B. Rock, D. L. McMullin, S. P. Jones, I.L. Lu, K. D. Eilers, D. R. Space, and A. McMullen Effect of Aircraft-Cabin Altitude on Passenger Discomfort N. Engl. J. Med., July 5, 2007; 357(1): 18 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Luks and E. R. Swenson Travel to high altitude with pre-existing lung disease Eur. Respir. J., April 1, 2007; 29(4): 770 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Chow, V. Browne, H. L. Heileson, D. Wallace, J. Anholm, and S. M. Green Ginkgo biloba and Acetazolamide Prophylaxis for Acute Mountain Sickness: A Randomized, Placebo-Controlled Trial Arch Intern Med, February 14, 2005; 165(3): 296 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Fiorenzano, M. Dottorini, A. L. Gabry, and C. Martin High-Altitude Pulmonary Edema Chest, October 1, 2003; 124(4): 1620 - 1621. [Full Text] [PDF] |
||||
![]() |
G. Ri-Li, P. J. Chase, S. Witkowski, B. L. Wyrick, J. A. Stone, B. D. Levine, and T. G. Babb Obesity: Associations with Acute Mountain Sickness Ann Intern Med, August 19, 2003; 139(4): 253 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Silber, P. Sonnenberg, D. J. Collier, A. J. Pollard, D. R. Murdoch, and P. J. Goadsby Clinical features of headache at altitude: A prospective study Neurology, April 8, 2003; 60(7): 1167 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Roach and P. H. Hackett Frontiers of hypoxia research: acute mountain sickness J. Exp. Biol., March 11, 2002; 204(18): 3161 - 3170. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Brundrett Sickness at high altitude: a literature review The Journal of the Royal Society for the Promotion of Health, March 1, 2002; 122(1): 14 - 20. [Abstract] [PDF] |
||||
![]() |
P. H. Hackett and R. C. Roach High-Altitude Illness N. Engl. J. Med., July 12, 2001; 345(2): 107 - 114. [Full Text] [PDF] |
||||
![]() |
N. Kinoshita, H. Yamazaki, S. Onishi, Y. Oguma, F. Katsukawa, and M. Horii Physiological Profile of Middle-Aged and Older Climbers Who Ascended Gasherbrum II, an 8035-m Himalayan Peak J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2000; 55(11): 630M - 633. [Abstract] [Full Text] |
||||
![]() |
J. Maloney, D. Wang, T. Duncan, N. Voelkel, and S. Ruoss Plasma Vascular Endothelial Growth Factor in Acute Mountain Sickness Chest, July 1, 2000; 118(1): 47 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Ryan and K. C. Kain Health Advice and Immunizations for Travelers N. Engl. J. Med., June 8, 2000; 342(23): 1716 - 1725. [Full Text] [PDF] |
||||
![]() |
B. Caruana-Montaldo, K. Gleeson, and C. W. Zwillich The Control of Breathing in Clinical Practice* Chest, January 1, 2000; 117(1): 205 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yaron, N. Waldman, S. Niermeyer, R. Nicholas, and B. Honigman The Diagnosis of Acute Mountain Sickness in Preverbal Children Arch Pediatr Adolesc Med, July 1, 1998; 152(7): 683 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Levine, J. H. Zuckerman, and C. R. deFilippi Effect of High-Altitude Exposure in the Elderly : The Tenth Mountain Division Study Circulation, August 19, 1997; 96(4): 1224 - 1232. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||